Status:
COMPLETED
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed to them by their doctor. The study will last for about ...
Eligibility Criteria
Inclusion
- Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol)
- The decision to initiate treatment with commercially available semaglutide has been made by the patient/Legally Acceptable Representative and the treating physician before and independently from the decision to include the patient in this study
- Male or female, age 18 years or older at the time of signing informed consent
- Diagnosed with type 2 diabetes at least 12 weeks prior to inclusion
- Available and documented haemoglobin A1c (HbA1c) value equal to or less than 12 weeks prior to initiation of semaglutide treatment
Exclusion
- Previous participation in this study. Participation is defined as having given informed consent in this study
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- Treatment with any investigational drug within 90 days prior to enrolment into the study
- Hypersensitivity to semaglutide or to any of the excipients
Key Trial Info
Start Date :
August 5 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 19 2021
Estimated Enrollment :
230 Patients enrolled
Trial Details
Trial ID
NCT04067999
Start Date
August 5 2019
End Date
July 19 2021
Last Update
September 24 2021
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
A Coruña, Spain, 15006
2
Novo Nordisk Investigational Site
Álava, Spain, 01001
3
Novo Nordisk Investigational Site
Barakaldo, Spain, 48903
4
Novo Nordisk Investigational Site
Barcelona, Spain, 08007